Co-treatment with arsenic trioxide and ganciclovir reduces tumor volume in a murine xenograft model of nasopharyngeal carcinoma

We have previously shown that disruption of promyelocytic leukemia nuclear bodies (PML NBs) is sufficient to activate the EBV lytic cycle thus making infected cells susceptible to ganciclovir (GCV) mediated killing in vitro. Here we show that co-administration of GCV and arsenic trioxide (ATO), a PM...

Descripción completa

Detalles Bibliográficos
Autores principales: Sides, Mark D, Sosulski, Meredith L, Luo, Fayong, Lin, Zhen, Flemington, Erik K, Lasky, Joseph A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666899/
https://www.ncbi.nlm.nih.gov/pubmed/23680002
http://dx.doi.org/10.1186/1743-422X-10-152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666899/
https://www.ncbi.nlm.nih.gov/pubmed/23680002
http://dx.doi.org/10.1186/1743-422X-10-152

Ejemplares similares